Understanding constipation-predominant IBS through community experiences and medical research.
Community experiences, not medical advice
Last editorial review: September 2026•Next review: March 2027
What is IBS-C?
Irritable Bowel Syndrome with Constipation (IBS-C) is one of the main subtypes of IBS. It is a functional gastrointestinal disorder: abdominal pain that keeps coming back, together with a bowel-habit change in which constipation is the dominant pattern — infrequent, hard or lumpy stools, and often straining or a feeling of incomplete evacuation. There is no identifiable organic cause on standard tests.
Rome IV defines the IBS-C pattern by stool form: at least 25% of bowel movements are Bristol Stool Scale types 1–2 (separate hard lumps or lumpy and sausage-like), and fewer than 25% are types 6–7 (loose or watery). This is how clinicians separate IBS-C from its siblings IBS-D (diarrhoea-predominant) and IBS-M (mixed).
NICE CG61 covers the diagnosis and management of IBS in adults in primary care, including first-line advice on diet, physical activity, and medicines aimed at the dominant bowel symptom. You can read the guideline on the NICE website.
How it is diagnosed
IBS-C is a clinical diagnosis based on the symptom pattern — not a self-test and not something a webpage can confirm. In UK primary care, a clinician will typically listen to the history (recurrent abdominal pain related to defecation, plus the constipation pattern), rule out red flags, and may run basic blood tests such as coeliac serology, as set out in NICE CG61. Stool-form diaries based on the Bristol Stool Scale are sometimes used to classify the subtype.
An important differential is chronic idiopathic constipation (CIC), which Rome criteria treat as distinct: in IBS-C, abdominal pain is a prominent, defining feature, whereas in CIC, pain is absent or not the main story. The two can be hard to tell apart in practice, and people sometimes move between the labels over time. Other work-up conversations a clinician may raise include slow transit constipation and dyssynergic defecation, and SIBO in some cases.
Common Symptoms
Abdominal pain and cramping, often related to bowel movements
Infrequent, hard, or difficult bowel movements (what counts as “infrequent” varies — Guts UK notes three times a day to three times a week can still be a normal range; change, difficulty, and hard stools usually matter more than a stopwatch)
Hard, lumpy stools (Bristol types 1–2)
Straining when going to the toilet
Feeling of incomplete evacuation
Bloating and visible abdominal distension
Excess gas and discomfort after meals
Common patterns people in the community describe
Symptoms that build across the day, with bloating often worst in the evening
Flare-ups linked to stress, travel, or changes in routine
A cycle of relying on laxatives, then stopping because they don't help the pain or bloating
Confusion about whether the label should be IBS-C or chronic constipation — especially when pain comes and goes
Important:
The information on this page comes from community experiences and published research. It is not medical advice, not a diagnosis, and not a treatment plan. Always talk to your GP or another qualified clinician before changing how you manage your symptoms — especially if you notice red flags such as unexplained weight loss, blood in your stool, or symptoms that wake you at night.
Approaches people discuss
These are options clinicians, guidelines, and community members discuss around IBS-C — not a self-treatment plan.
Established First-line NICE CG61 care: dietary review (prefer soluble fibre such as ispaghula/psyllium, not bran), physical activity advice, and general IBS management in primary care, with laxatives considered for constipation when diet and lifestyle measures have not helped. NICE CG61 says to avoid lactulose. Sources: NICE CG61; NHS IBS; BSG 2021; ACG 2021.
Established Asking a clinician about IBS-C-targeted prescription options such as linaclotide, a gut-targeted secretagogue with trial evidence for both constipation and abdominal pain in IBS with constipation. Source: Layer P et al., Aliment Pharmacol Ther 2014, PMC4305214.
Established Clinician review of the IBS-C vs chronic idiopathic constipation (CIC) pathway when abdominal pain is not prominent — bowel symptoms overlap, and the care path can differ. This is a clinician conversation, not a self-label. Sources: Rome IV criteria; NICE CG61; NHS.
Emerging Newer gut-targeted secretagogues and bile-acid modulation approaches being studied for IBS-C and functional constipation; a 2025 scoping review maps how guidelines currently handle IBS-C and functional constipation. Source: BMC Gastroenterology 2025 scoping review.
Emerging Dietitian-supervised low-FODMAP trial, then reintroduction — a time-limited assessment after first-line advice, not a forever restriction. For constipation-predominant patterns, restrictive phases can worsen hard stools for some people; opioid pain medicines can also worsen constipation and need a clinician review, not DIY stacking of laxatives. Sources: NICE CG61; BSG 2021; Guts UK; ACG 2021.
What not to self-manage
These are cautions, not approaches people discuss:
Do not stay on over-the-counter laxatives for years without a review — long-term self-managed use without clinician oversight is a frequent regret; ask for a review of the constipation and pain picture together.
Do not treat IBS-C as “just constipation” — ignoring the abdominal-pain side of the pattern can miss the IBS-C vs CIC distinction and the wrong care path.
Do not self-diagnose the IBS subtype from a webpage or stool app — subtype labelling and red-flag checks belong with a GP or gastroenterologist (NICE CG61; NHS).
Do not stack laxatives on top of opioid pain medicines without clinician advice — opioids commonly worsen constipation; that combination needs a medicines review, not home titration.
Medical Research
NICE CG61 — IBS diagnosis and management (2015 update)
The NICE guideline for diagnosing and managing IBS in adults in primary care. It covers the positive diagnostic criteria, tests to rule out other causes (including coeliac serology), and first-line management of the constipation pattern seen in IBS-C.
A systematic review and meta-analysis of IBS prevalence worldwide using Rome III and Rome IV criteria, published in the Lancet Gastroenterology & Hepatology. It reports how common IBS is globally and how prevalence shifts with the stricter Rome IV definition — the framework behind the IBS-C subtype.
Linaclotide for IBS with constipation (Layer et al. 2014)
A review of linaclotide — a gut-targeted secretagogue — for IBS with constipation, covering trial evidence for improvements in both bowel movements and abdominal pain. Linaclotide is one of the few treatments studied specifically in the IBS-C population rather than IBS more broadly.